Practice Test Geeks(ADM) Board Certified Addiction Medicine Specialist Practice Test
← All ADM Flashcard Decks

Treatment Protocols & Procedures Flashcards

7 cards from real ADM practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.

Read the first 7 Treatment Protocols & Procedures flashcards as text

  1. A patient with benzodiazepine use disorder wants to discontinue alprazolam 4 mg/day. Which conversion and taper strategy is most appropriate?

    Answer: Convert to an equivalent dose of a long-acting benzodiazepine such as diazepam, then taper by 5–10% every 1–2 weeks

    Converting to a long-acting benzodiazepine like diazepam and tapering slowly (5–10%/1–2 weeks) minimizes seizure risk and withdrawal severity.

  2. Which of the following best describes the goal of Medication-Assisted Treatment (MAT) according to SAMHSA?

    Answer: To use FDA-approved medications combined with counseling and behavioral therapies to treat substance use disorders

    SAMHSA defines MAT as the combination of FDA-approved medications with counseling and behavioral therapies as a whole-patient approach to treating SUDs.

  3. Which intervention is the most evidence-based first-line approach for cannabis use disorder in adults?

    Answer: Cognitive Behavioral Therapy (CBT) combined with Motivational Enhancement Therapy (MET)

    Combined CBT and MET (often with contingency management) has the strongest evidence for cannabis use disorder, as no pharmacotherapy is FDA-approved.

  4. A patient presents to the ED with opioid overdose and receives naloxone. After stabilization, which action is most consistent with best practice for OUD?

    Answer: Offer buprenorphine initiation in the ED and connect to outpatient OUD treatment before discharge

    Emergency department-initiated buprenorphine with warm handoff to outpatient care significantly improves treatment engagement and reduces subsequent overdose.

  5. Contingency management (CM) is most effective for which substance use disorder?

    Answer: Stimulant use disorder (cocaine and methamphetamine)

    Contingency management has the strongest evidence base for stimulant use disorders, providing tangible rewards for drug-free urine screens.

  6. Which of the following is a contraindication to initiating extended-release injectable naltrexone (Vivitrol) for opioid use disorder?

    Answer: Current physiological opioid dependence without prior opioid-free period of 7–10 days

    Naltrexone will precipitate acute withdrawal in physiologically dependent patients; a 7–10-day opioid-free period is required before initiation.

  7. A physician practicing in an office-based opioid treatment (OBOT) setting wants to prescribe buprenorphine. Under the 2023 SUPPORT Act changes, what is required?

    Answer: A standard DEA registration is sufficient; the DATA 2000 waiver (X-waiver) requirement has been eliminated

    The Consolidated Appropriations Act of 2023 eliminated the X-waiver requirement; any DEA-licensed provider can now prescribe buprenorphine for OUD.